Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$9.49 USD
-0.53 (-5.29%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $9.49 0.00 (0.00%) 4:56 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INO 9.49 -0.53(-5.29%)
Will INO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INO
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?
INO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
Other News for INO
INOVIO Reports Inducement Grant Under Inducement Plan
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
Inovio's INO-3107 granted Advanced Therapy Medicinal Product Certificate by EMA
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway